Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Debt to Equity (2016 - 2025)

IGC Pharma has reported Debt to Equity over the past 15 years, most recently at $0.02 for Q3 2025.

  • Quarterly Debt to Equity fell 10.86% to $0.02 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $0.02 through Sep 2025, down 10.86% year-over-year, with the annual reading at $0.02 for FY2025, 13.12% up from the prior year.
  • Debt to Equity was $0.02 for Q3 2025 at IGC Pharma, down from $0.02 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.02 in Q2 2025 and troughed at $0.0 in Q2 2021.
  • The 5-year median for Debt to Equity is $0.01 (2023), against an average of $0.01.
  • The largest YoY upside for Debt to Equity was 838.42% in 2021 against a maximum downside of 81.41% in 2021.
  • A 5-year view of Debt to Equity shows it stood at $0.01 in 2021, then skyrocketed by 53.31% to $0.01 in 2022, then skyrocketed by 98.03% to $0.02 in 2023, then soared by 40.45% to $0.02 in 2024, then fell by 23.81% to $0.02 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Debt to Equity are $0.02 (Q3 2025), $0.02 (Q2 2025), and $0.02 (Q1 2025).